

## Osteocalcin in serum, saliva and gingival crevicular fluid: their relation with periodontal treatment outcome in postmenopausal women

Pedro Bullón <sup>1</sup>, Lucy Chandler <sup>1</sup>, Juan J. Segura Egea <sup>1</sup>, Ramón Pérez Cano <sup>2</sup>, Ángel Martínez Sahuquillo <sup>1</sup>

(1) Periodontics Department

(2) Medicine Department, School of Medicine, University of Sevilla

### Correspondence:

Prof. Pedro Bullón Fernández

Cl Luis Montoto 105 - 1º

41007 - Sevilla

E-mail: pbullon@us.es

Received: 20-02-2006

Accepted: 25-03-2007

Bullón P, Chandler L, Segura-Egea JJ, Pérez-Cano R, Martínez-Sahuquillo A. Osteocalcin in serum, saliva and gingival crevicular fluid: their relation with periodontal treatment outcome in postmenopausal women. Med Oral Patol Oral Cir Bucal 2007;12:E193-7.

© Medicina Oral S. L. C.I.F. B 96689336 - ISSN 1698-6946

### Indexed in:

-Index Medicus / MEDLINE / PubMed  
-EMBASE, Excerpta Medica  
-SCOPUS  
-Índice Médico Español  
-IBECS

### ABSTRACT

**Background.** Osteocalcin levels have been postulated as a marker of inhibition of bone formation. The aim of the present study was to assess plasma, saliva and GCF levels of osteocalcin and correlate them with periodontal treatment outcome in postmenopausal women.

**Methods.** Thirty-nine postmenopausal women ( $57.8 \pm 8.5$  years old) were recruited for the study. Periodontal examination of all women was carried out and plaque, bleeding on probing, probing depth (PD), and clinical attachment level (CAL) were recorded. Serum, saliva and gingival crevicular fluid osteocalcin were measured. Then, periodontal treatment was carried out. Six months after the first appointment a second periodontal examination was carried out.

**Results.** Mean PD and mean CAL decreased significantly at second appointment in the group with serum osteocalcin concentration  $< 10$  ng/ml ( $15.8 \pm 15.8\%$  and  $15.3 \pm 21.2\%$  respectively;  $p < 0.05$ ). Mean PD decreased significantly at second appointment in the groups with saliva osteocalcin concentration  $< 3$  ng/ml ( $17.1 \pm 15.9\%$ ;  $p < 0.05$ ) and  $3 - 7$  ng/ml ( $16.2 \pm 18.1\%$ ;  $p < 0.05$ ).

**Conclusions.** Low serum osteocalcin concentration is associated to a significantly higher percentage of decrease in PD and CAL after periodontal treatment in postmenopausal women. Low saliva osteocalcin concentrations are significantly associated to a higher percentage of decrease in PD.

**Key words:** Osteocalcin, osteoporosis, periodontitis.

### RESUMEN

**Antecedentes.** Los niveles de osteocalcina se han propuesto como marcador de la inhibición de la formación ósea. El propósito de este trabajo es determinar las concentraciones de osteocalcina en plasma, saliva y fluido crevicular correlacionándolo con el resultado del tratamiento periodontal en mujeres postmenopáusicas.

**Pacientes y métodos.** El estudio se realizó en treinta y nueve mujeres postmenopáusicas ( $57.8 \pm 8.5$  años de edad). El examen periodontal incluyó el control de placa, el sangrado al sondaje, la profundidad de sondaje (PS) y la pérdida de inserción (CAL). Se determinaron los niveles de osteocalcina en suero, saliva y fluido crevicular. A continuación se llevó a cabo el tratamiento periodontal. Pasados seis meses tras la primera cita se llevó a cabo un segundo examen periodontal.

**Resultados.** Las medias de la PS y del CAL disminuyeron significativamente en el segundo examen periodontal en el grupo de mujeres con osteocalcina en suero  $< 10$  ng/ml ( $15.8 \pm 15.8\%$  y  $15.3 \pm 21.2\%$ , respectivamente;  $p < 0.05$ ). La PS media disminuyó significativamente en el segundo examen en los grupos con concentraciones de osteocalcina en saliva  $< 3$  ng/ml ( $17.1 \pm 15.9\%$ ;  $p < 0.05$ ) y  $3 - 7$  ng/ml ( $16.2 \pm 18.1\%$ ;  $p < 0.05$ ).

**Conclusiones.** Los niveles bajos de osteocalcina en suero se asocian significativamente a un mayor porcentaje de disminución de la PS y del CAL tras el tratamiento periodontal en mujeres postmenopáusicas. Las bajas concentraciones de osteocalcina en saliva se asociaron significativamente a un mayor porcentaje de disminución de la PS.

**Palabras clave:** *Osteocalcina, osteoporosis, periodontitis.*

## INTRODUCTION

Periodontitis is an inflammatory disease usually leading to loss of bone. In periodontitis, there is an increased turnover of alveolar bone although there may be a dominance of bone resorption over bone formation, leading to alveolar bone loss and loss of attachment (1). Increase in bone resorption due to gonadal reasons, and accelerated loss of bone in the first decade after menopause appear to be the main pathogenic factors in women (2).

Serum osteocalcin is presently considered a valid marker of bone turnover when resorption and formation are coupled and a specific marker of bone formation when formation and resorption are uncoupled (3). Gingival crevicular fluid (GCF), which is an exudate that can be harvested from the sulcus or periodontal pocket, has been regarded as a promising medium for the detection of periodontal disease activity (4,5). So, the majority of new diagnostic tests for periodontal disease utilize GCF (6,7). Several investigations on osteocalcin levels in GCF from patients with periodontitis (8-12) have been reported, suggesting that osteocalcin levels in GCF may reflect inflammation at diseased sites and there has been recent interest in osteocalcin as a potential marker of bone turnover in periodontal disease (1,3). But the role of osteocalcin in periodontal disease progression and periodontal treatment outcome is still unclear.

The aim of the present study was to assess plasma, saliva and GCF levels of osteocalcin and correlate it with periodontal treatment outcome in postmenopausal periodontally diseased women.

## MATERIALS AND METHODS

### *Subjects selection and clinical examination*

For 2 years all the periodontally diseased women with more than one year after menopausal attended in our Dental School, were proposed to participate in the study. The initial sample consisted of 81 women but the final sample was reduced to 39 women because some did not follow the treatment in their totality and others did not return to revision. Our protocol and consent forms were approved by the Committee of Ethics and Research of the University Hospital "Virgen Macarena". Periodontal examination of all women was carried out and the following measurements were recorded: a) O'Leary plaque index (13), b) Van der Velden bleeding on probing index (14), c) probing depth (PD): measured from the gingival margin to the most apical penetration of the probe, and d) recession was measured, from the cemento-enamel junction to the gingival margin. Clinical attachment level (CAL) was calculated adding recession to PD. PD and CAL were assessed at six sites per tooth: mesial edge, midtooth, and distal edge on both facial

and lingual sides. Women were classified as periodontally diseased according to the criteria established by Machtei (15): the clinical entity of periodontitis is suggested based on the presence of CAL  $\geq$  6 mm in two or more teeth and one or more sites with PD  $\geq$  5 mm. Moreover, all the women had to meet the following criteria: at least 12 months since the last menstrual period, at least three functional teeth, no taking hormone therapy, no receiving medical treatment influencing the bone metabolism, no suffering any metabolic diseases, and without densitometric diagnosis of osteoporosis.

In the first appointment some general data were recorded: age, age at menopause, years since menopause, and cigarette smoking. Samples for the determination of osteocalcin concentration in serum, saliva and gingival crevicular fluid were taken, and a densitometry was prescribed. Following baseline examination, all patients were instructed in oral hygiene and scaling and root planning was performed under local anaesthesia in 4 sessions.

Six months after the first appointment a second periodontal examination of all patients was carried out. Samples for the determination of osteocalcin concentration in serum, saliva and gingival crevicular fluid were also taken. Percentages of variation of PD and CAL between the first and the second appointments were calculated by subtracting both determinations and expressing this value as percentage of the first determination.

### *Sample collection and analytical determinations*

Blood was centrifuged to obtain plasma. Gingival crevicular fluid (GCF) sampling was performed based on the previously method described by Nomura et al. (16,17). Each subject was monitored at 4 sites in the upper incisors teeth. The sites always were PD  $\geq$  5 mm. After isolation from saliva, the area around each site sampled was dried and supragingival plaque removed. GCF was collected for 2 minutes using four strips (20 x 4 mm) of Whatmann 1 paper (Whatmann Lab Sales Ltd, Maidstone, Kent, UK). Each strip was placed gently into the gingival crevice until slight resistance was felt, and GCF volume was collected. The GCF absorbed ( $\mu$ l) / wet area ( $\text{mm}^2$ ) in the strip paper was calculated by comparing it to the amount of a standard plasma containing a low concentration of 125I used as a tracer that the strip can absorb, similar to what has been described for blood specimens (18,20). A saliva sample was also collected from the sublingual zone with the same paper strips. The plasma, saliva and GCF samples were placed in a microcentrifuge tube and vortexed in 200  $\mu$ l of extraction buffer consisting of 0.5 NaCl, 50mM Tris-HCL (ph 7.4), 5 mM CaCl<sub>2</sub> and 0.05% Brij 35 (polyoxyethylene lauryl ether), following the method described by Lee et al. (20).

### Osteocalcin assay

Osteocalcin measurements in serum, saliva and GCF were made using an electrochemiluminescence technique described previously (12).

### Statistical analysis

Data are expressed as means  $\pm$  standard deviation. Differences between groups in normally continuous variables were assessed by analysis of variance (ANOVA), using the Bonferroni test to establish differences between groups. Discrete variables were analysed by mean of the frequencies distribution.

## RESULTS

The mean age of the 39 women was  $57.8 \pm 8.5$  years. Only four of them were smoker. Mean menopausal age was  $48.3 \pm 5.7$ . Mean number of years since menopause was  $9.61 \pm 8.1$ .

Mean PD, mean CAL, and mean BOP decreased significantly after periodontal treatment ( $p < 0.01$ ) (Table 1). There were no significant differences in the percentage of sites with plaque between first and second appointment.

Variations in PD and CAL were analysed according to serum osteocalcin levels (Table 2). In two patients it was not possible to obtain serum samples. Patients were classified in two groups according to the osteocalcin level in serum: a)  $< 10$  ng/ml osteocalcin concentration ( $n = 29$ ); and b)  $> 10$  ng/ml osteocalcin concentration ( $n = 8$ ). PD and CAL were significantly higher both in the first and second appointments in the group with serum osteocalcin concentration  $> 10$  ng/ml ( $p < 0.05$ ). Mean PD and mean CAL decreased significantly at second appointment, after periodontal treatment, in the group with serum osteocalcin concentration  $< 10$  ng/ml ( $-15.8 \pm 15.8\%$  and  $-15.3 \pm 21.2\%$  respectively;  $p < 0.05$ ). In the group with serum osteocalcin concentration  $> 10$  ng/ml mean PD decreased significantly at second appointment ( $-17.6 \pm 13.3\%$ ;  $p < 0.05$ ) but CAL did not differ ( $-17.4 \pm 29.7\%$ ;  $p > 0.05$ ). There were not found significant differences between the two groups in PD and CAL percentages of variation between the first and second appointments.

Variations in PD and CAL were analysed according to GCF osteocalcin levels (Table 3). Patients were classified in three groups according to the osteocalcin level in GCF: a)  $< 12$  ng/ml osteocalcin concentration ( $n = 10$ ); b)  $12 - 30$  ng/ml ( $n = 9$ ); and c)  $> 30$  ng/ml osteocalcin concentration ( $n = 20$ ). There were not significant differences between the three groups in PD and CAL neither in the first nor in the second appointments. Mean PD and mean CAL did not vary significantly at second appointment, after periodontal treatment, in the three groups. PD and CAL percentages of variation between the first and second appointment did not differ significantly in the three groups.

Variations in PD and CAL were analysed according to saliva osteocalcin levels (Table 4). Patients were classified in three groups according to the osteocalcin level in saliva: a)  $< 3$  ng/ml osteocalcin concentration ( $n = 10$ ); b)  $3-7$  ng/ml ( $n = 20$ ); and c)  $> 7$  ng/ml osteocalcin concentration ( $n =$

9). There were not significant differences between the three groups in PD and CAL neither in the first nor in the second appointments. Mean PD decreased significantly at second appointment, after periodontal treatment, in the groups with saliva osteocalcin concentration  $< 3$  ng/ml ( $-17.1 \pm 15.9\%$ ;  $p < 0.05$ ) and  $3 - 7$  ng/ml ( $-16.2 \pm 18.1\%$ ;  $p < 0.05$ ). PD and CAL percentages of variation between the first and second appointment did not differ significantly in the three groups.

**Table 1.** Clinical characteristics of periodontally diseased postmenopausal women in the first and second appointments (mean  $\pm$  SD).

	1 <sup>st</sup> appointment	2 <sup>nd</sup> appointment	P
PD (mm)	$2.6 \pm 0.5$	$2.2 \pm 0.4$	$< 0.01$
CAL (mm)	$3.5 \pm 1.1$	$3.0 \pm 0.8$	$< 0.01$
BOP (%)	$73.3 \pm 17.7$	$56.9 \pm 20.6$	$< 0.01$
Plaque (%)	$67.0 \pm 30.1$	$71.2 \pm 23.2$	$> 0.05$

PD: Probing depth.

BOP: Bleeding on probing index.

CAL: Clinical attachment level.

**Table 2.** Variations in PD and CAL between the first and second appointments and their relation with serum osteocalcin concentrations (ng/ml).

	$< 10$ ng/ml n = 29	$> 10$ ng/ml n = 8	p
1 <sup>st</sup> - Mean PD (mm)	$2.53 \pm 0.4$	$3.01 \pm 0.5$	0.01
2 <sup>nd</sup> - Mean PD (mm)	$2.13 \pm 0.4$	$2.48 \pm 0.4$	0.03
1-2 PD variation (%)	$-15.8 \pm 15.8^{**}$	$-17.6 \pm 13.3^{**}$	$> 0.05$
1 <sup>st</sup> - Mean CAL (mm)	$3.33 \pm 0.8$	$4.38 \pm 1.6$	0.01
2 <sup>nd</sup> - Mean CAL (mm)	$2.82 \pm 0.5$	$3.62 \pm 1.4$	0.01
1-2 CAL variation (%)	$-15.3 \pm 21.2^{**}$	$-17.4 \pm 29.7^*$	$> 0.05$

\*1st vs 2nd appointment  $p > 0.05$ .

\*\*1st vs 2nd appointment  $p < 0.05$ .

PD: Probing depth.

CAL: Clinical attachment level.

**Table 3.** Variations in PD and CAL between the first and second appointments and their relation with GCF osteocalcin concentrations (ng/ml).

	< 12 ng/ml n = 10	12 – 30 ng/ml n = 9	>30 ng/ml n = 20	P
1 <sup>st</sup> - Mean PD (mm)	2.35 ± 0.3	2.61 ± 0.5	2.79 ± 0.5	0.06
2 <sup>nd</sup> - Mean PD (mm)	2.08 ± 0.3	2.31 ± 0.4	2.22 ± 0.4	0.47
1-2 PD variation (%)	-11.5 ± 12.8*	-11.5 ± 19.2*	-20.4 ± 17.9*	>0.05
1 <sup>st</sup> - Mean CAL (mm)	3.24 ± 1.4	3.60 ± 0.8	3.66 ± 1.0	0.58
2 <sup>nd</sup> - Mean CAL (mm)	2.86 ± 1.3	3.09 ± 0.5	2.97 ± 0.7	0.84
1-2 CAL variation (%)	-11.7 ± 43.2*	-14.2 ± 13.9*	-18.8 ± 13.7*	>0.05

\*1st vs 2nd appointment p &gt; 0.05.

\*\*1st vs 2nd appointment p &lt; 0.05.

PD: Probing depth.

CAL: Clinical attachment level.

**Table 4.** Variations in PD and CAL between the first and second appointments and their relation with saliva osteocalcin concentrations (ng/ml).

	< 3 ng/ml n = 10	3 - 7 ng/ml n = 20	> 7 ng/ml n = 9	P
1 <sup>st</sup> - Mean PD (mm)	2.51 ± 0.4	2.77 ± 0.5	2.46 ± 0.5	0.19
2 <sup>nd</sup> - Mean PD (mm)	2.08 ± 0.4	2.32 ± 0.4	2.08 ± 0.4	0.18
1-2 PD variation (mm)	17.1 ± 15.9**	16.2 ± 18.1**	15.4 ± 20.3*	>0.05
1 <sup>st</sup> - Mean CAL (mm)	3.10 ± 0.6	3.87 ± 1.2	3.29 ± 0.8	0.12
2 <sup>nd</sup> - Mean CAL (mm)	2.57 ± 0.6	3.25 ± 1.0	2.81 ± 0.4	0.09
1-2 CAL variation (%)	17.1 ± 19.4*	16.0 ± 31.0*	14.6 ± 24.3*	>0.05

\*p &gt; 0.05; \*\*p &lt; 0.05

PD: Probing depth.

CAL: Clinical attachment level.

## DISCUSSION

Using a longitudinal design, the periodontal treatment outcome in postmenopausal women and its correlation with GCF, saliva and serum osteocalcin concentrations has been studied. We showed that low serum osteocalcin concentration is associated to a significantly higher percentage of decrease in PD and CAL after periodontal treatment in postmenopausal women. We also showed that low saliva osteocalcin concentrations are significantly associated to a higher percentage of decrease in PD.

In a cross-sectional study carried out by Lee et al. (1) including 20 patients, no difference in GCF osteocalcin levels were observed between sites with and without periodontal pockets in the same patient. Recently, Wilson et al. (11) in a study including 14 patients without periodontal treatment, did not detect osteocalcin in GCF. However, most of these studies (1,10) have been carried out in periodontal patients and did not compare healthy and diseased subjects, but osteocalcin levels in healthy and periodontally affected sites in periodontal patients.

On the contrary, serum osteocalcin concentration correlated significantly with the periodontal treatment outcome. The use of serum osteocalcin as osteoporosis marker has been studied in 295 women over 67 years, without treatment with estrogens. The authors (21) conclude that high serum osteocalcin levels are associated with fast bone loss, but the individual value of this marker is limited. In some animal experimental models it has been possible to verify that serum osteocalcin levels are determinant of the bone formation (22-24) and it has been showed "in vitro" that has a role in the bone resorption process (25,26). Nevertheless, we must to be in mind that osteocalcin is produced by osteoblasts and only a small fraction is secreted directly in the circulation (27).

We can conclude that low serum osteocalcin concentration is associated to a significantly higher percentage of decrease in PD and CAL after periodontal treatment in postmenopausal women. Low saliva osteocalcin concentrations are significantly associated to a higher percentage of decrease in PD.

## REFERENCES

- Lee AJ, Walsh TF, Hodges SJ, Rawlinson A. Gingival crevicular fluid osteocalcin in adult periodontitis. *J Clin Periodontol* 1999;26:252-6.
- Riggs BL, Melton LJ. Evidence for two distinct syndromes of involutional osteoporosis. *Am J Med* 1986;75:899-901.
- Giannobile WV, Al-Shammari KF, Sarment DP. Matrix molecules and growth factors as indicators of periodontal disease activity. *Periodontol* 2000 2003;31:125-34.
- Curtis MA, Gillett IR, Griffiths GS, Maiden MF, Sterne JA, Wilson D et al. Detection of high-risk groups and individuals for periodontal diseases: laboratory markers from analysis of gingival crevicular fluid. *J Clin Periodontol* 1989;16:1-11.
- Page RC. Host response tests for diagnosing periodontal diseases. *J Periodontol* 1992;63:356-66.
- Griffiths GS. Formation, collection and significance of gingival crevice fluid. *Periodontol* 2000 2003;31:32-42.
- Uitto V-J, Overall CM, McCulloch C. Proteolytic host cell enzymes in gingival crevice fluid. *Periodontol* 2000 2003;31:77-104.
- Kunimatsu K, Matakis S, Tanaka H, Mine N, Kiyoki M, Hosoda K et

- al. A cross-sectional study on osteocalcin levels in gingival crevicular fluid from periodontal patients. *J Periodontol* 1993;64:865-9.
- Nakashima K, Roehrich N, Cimasoni G. Osteocalcin, prostaglandin E2 and alkaline phosphatase in gingival crevicular fluid: their relations to periodontal status. *J Clin Periodontol* 1994;21:327-33.
- Nakashima K, Giannopoulos C, Andersen E, Roehrich N, Brochut P, Dubrez B et al. A longitudinal study of various crevicular fluid components as markers of periodontal disease activity. *J Clin Periodontol* 1996;23:832-8.
- Wilson AN, Schmid MJ, Marx DB, Reinhardt RA. Bone turnover markers in serum and periodontal microenvironments. *J Period Res* 2003; 38:355-61.
- Bullón P, Goberna B, Guerrero JM, Segura JJ, Pérez-Cano R, Martínez-Sahuquillo A. Serum, saliva, and gingival crevicular fluid osteocalcin: their relation to periodontal status and bone mineral density in postmenopausal women. *J Periodontol* 2005;76:513-9.
- O'Leary TJ, Drake RB, Naylor JE. The plaque control record. *J Periodontol* 1972;43:38-41.
- Van der Velden U. Probing force and relationship of the probe tip to the periodontal tissues. *J Clin Periodontol* 1979;6:106-14
- Machtei EE, Christersson LA, Grossi SG, Dunford R, Zambon JJ, Genco RJ. Clinical criteria for the definition of established periodontitis. *J Periodontol* 1992;63:207-15.
- Nomura T, Ishii A, Shimizu H, Taguchi N, Yoshie H, Kusakari H et al. Tissue inhibitor of metalloproteinases-1, matrix metalloproteinases-1 and -8, and collagenase activity levels in peri-implant crevicular fluid after implantation. *Clin Oral Implants Res* 2000;11:430-40
- Oringer RJ, Al-Shammari KF, Aldredge WA, Iacono VJ, Eber RM, Wang H-L et al. Effect of locally delivered minocycline microspheres on markers of bone resorption. *J Periodontol* 2002;73:835-42.
- Gonzalez C, Guerrero JM, Elorza FL, Molinero P, Goberna R. Evaluation of maternal serum alpha-fetoprotein assay using dry blood spot samples. *J Clin Chem* 1988;26:79-84
- Chamoles NA, Blanco MB, Gaggioli C. Hurthler-like phenotype: enzymatic diagnosis in dried blood spots on filter paper. *Clin Chem* 2001; 47:2098-102
- Lee HJ, Auken S, Kulkarni G, Birek P, Overall CM, Sodek J et al. Collagenase activity in recurrent periodontics: relationship to disease progression and doxycyclin therapy. *J Per Research* 1991;26:479-85.
- Bauer DC, Sklarin PM, Stone K, Black DM. Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures. *J Bone Miner Res* 1999; 14: 1404-10.
- Lopez-Marcos JF, Garcia-Valle S, Garcia-Iglesias AA. Periodontal aspects in menopausal women undergoing hormone replacement therapy. *Med Oral Patol Oral Cir Bucal* 2005;10:132-41.
- Castro CE, Koss MA, Lopez ME. Biochemical markers of the periodontal ligament. *Med Oral* 2003;8:322-8.
- Frutos R, Rodriguez S, Miralles-Jorda L, Machuca G. Oral manifestations and dental treatment in menopause. *Med Oral* 2002;7:26-30, 31-5.
- Ducy P, Desbois C, Boyce B, Pinero G, Story B. Increased bone formation in osteocalcin deficient mice. *Nature* 1996;382:448-52.
- Chenu C, Colucci S, Grano M, Zigrino P, Barattolo R. Osteocalcin induce chemotaxis, secretion of matrix proteins, and calcium-mediated intracellular signaling in human osteoclast-like cells. *J Cell Biol* 1994; 127:1149-58.
- Lian JB, Gundberg M. Osteocalcin: biochemical consideration and clinical applications. *Clin Orthop* 1988;226:267-91.